Expert Insights on Novel NMOSD Treatments : Episode 8
Opinion
Video
Meningococcal Infection and NMOSD
Author(s):
Key Takeaways
- Eculizumab and ravulizumab increase meningococcal infection risk, necessitating vaccination in treated patients.
- Phase 3 and long-term studies emphasize the need for vigilant monitoring and prophylactic measures despite vaccination.
Sean Pittock, MD, discusses the risks of meningococcal infection associated with eculizumab and ravulizumab in phase 3 and long-term extension studies, as well as his interpretation of the concerns surrounding meningococcal vaccination and its potential impact on relapse activity.
EP: 1.Relapses and Disability Accumulation in NMOSD
EP: 2.Treatments With Higher Efficacy and Relapses in NMOSD
EP: 3.Ravulizumab Long-Term Data and Management of NMOSD
EP: 4.The Evolving Understanding of NMOSD Pathophysiology and the Role of Complement System
EP: 5.Treatment Options to Manage and Prevent Relapses in NMOSD
EP: 6.Importance of Diverse Mechanisms of Action to Effectively Treat NMOSD
EP: 7.Complement Inhibitors in NMOSD
Now Viewing
EP: 8.Meningococcal Infection and NMOSD
Video content above is prompted by the following:
- Discuss the risk of meningococcal infection with eculizumab and ravulizumab in phase 3 and long-term extension studies.
- There may be concerns with meningococcal vaccination and its impact on relapse activity. What is your interpretation of these data?
Related Videos
Related Content
